Skip to content

13F-HR filed by Commodore Capital LP

Commodore Capital LP filed this 13F-HR for the quarter ended 2020-12-31, filed 2021-02-16, with 28 holding rows worth $183,931,000.

Accession
0001831942-21-000002
Filed
2021-02-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2020

A holdings report, 28 entries on the cover page, a total value of $183,931,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $183,931,000 with VALUE read as thousands by filing date, 13F file number 028-20976. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
C4 THERAPEUTICS INC12529R107COM STK481,094$15,939,000thousands by filing date
TRILLIUM THERAPEUTICS INC COM NEW89620X506Stock852,871$12,546,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock423,708$12,203,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock532,000$9,049,000thousands by filing date
KRONOS BIO INC50107A104COM298,839$8,926,000thousands by filing date
IVERIC BIO INC46583P102COM1,274,261$8,805,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock1,336,275$8,646,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM760,025$8,535,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM1,486,107$8,530,000thousands by filing date
PMV PHARMACEUTICALS INC69353Y103COM125,000$7,689,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM330,315$7,346,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock467,368$7,188,000thousands by filing date
PROTAGONIST THERAPEUTICS74366E102COM347,500$7,006,000thousands by filing date
MEREO BIOPHARMA GROUP PLC589492107CMN1,854,278$6,638,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW356,431$6,245,000thousands by filing date
VISTAGEN THERAPEUTICS INC92840H202COM3,150,000$6,111,000thousands by filing date
RELMADA THERAPEUTICS INC75955J402COMMON STOCK178,565$5,727,000thousands by filing date
ARS PHARMACEUTICALS INC82835W108COM97,143$4,502,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock133,503$4,360,000thousands by filing date
SURFACE ONCOLOGY INC86877M209COM467,796$4,322,000thousands by filing date
GENOCEA BIOSCIENCES INC372427401COMMON STOCK1,765,901$4,273,000thousands by filing date
Mersana Therapeutics Inc59045L106Common Stock158,827$4,226,000thousands by filing date
IMMUNOVANT INC45258J102COM83,782$3,870,000thousands by filing date
INVENTIVA SA46124U107ADS231,000$3,350,000thousands by filing date
BCLS ACQUISITION CORPG0904B105CMN250,000$2,785,000thousands by filing date
CYCLACEL PHARMACE 6percent PFDCONV23254L603Stock264,690$2,067,000thousands by filing date
MILLENDO THERAPEUTICS INC60040X103COM925,000$1,980,000thousands by filing date
LIFESCI ACQUISITION II CORP53229E103COM100,000$1,067,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001831942-21-000002this filing2021-02-16acceptance time not in the bulk data set